# Clinical Trials Data KIT - Document 75

# Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy

## Clinical Trial: https://clinicaltrials.gov/study/NCT01219452

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Children of both genders with established clinical and echocardiographic diagnosis of dilated cardiomyopathy whose parents accept to participate in the trail.\n\* They should have symptoms and /or signs of heart failure, despite optimized medical treatment.\n\* Ejection fraction of left ventricular should be less than 50%, but more than 20%.\n\nExclusion Criteria:\n\n\* associate coronary artery disease.\n\* any history or suspicion of a toxic , pharmacologic or deposit etiology.\n\* associated malignant or pre -malignant systemic disease.\n\* associated hematologic disorder.\n\* a history of sustained ventricular tachycardia or fibrillation.\n\* a history of syncope during the previous year, or with an active infectious disease or positive tests to viral disease.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "1 Year",  
"stdAges": [  
"CHILD"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient's eligibility is determined by factors related to their diagnosis of dilated cardiomyopathy, heart function, and presence of certain conditions or histories. The criteria do not mention a KIT gene mutation as either an inclusion or exclusion factor. Therefore, the presence of a KIT gene mutation does not impact eligibility directly. However, the patient must meet the specified inclusion criteria and must not meet any exclusion criteria. If the KIT gene mutation is unrelated to any of the specified exclusion conditions (such as malignant disease, hematologic disorders, etc.), it would not automatically disqualify the patient from the trial. It's always a good practice to confirm such specifics with the study's contact person or study coordinator.